SEC Filings
Cencora Splits Into Two Reportable Segments, And Its Specialty Arm Posts A 3.73% Margin
Cencora recast fiscal 2026 and 2025 results under the structure it will use from fiscal 2027, with total revenue of $337.4 billion.
Cencora (COR) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
SEC Filings
Cencora recast fiscal 2026 and 2025 results under the structure it will use from fiscal 2027, with total revenue of $337.4 billion.
Earnings
The drug distributor also splits its business into new segments, with fourth-quarter adjusted earnings of $4.66 a share, up 21.4%.
Deals
Cencora would pay about $1.7 billion to lift its stake to 75%, and says fiscal 2026 adjusted EPS will be at least $17.90.